title: The influence of 150-cavity binders on the dynamics of influenza A neuraminidases as revealed by molecular dynamics simulations and combined clustering.
abstract: Neuraminidase inhibitors are the main pharmaceutical agents employed for treatments of influenza infections. The neuraminidase structures typically exhibit a 150-cavity, an exposed pocket that is adjacent to the catalytic site. This site offers promising additional contact points for improving potency of existing pharmaceuticals, as well as generating entirely new candidate inhibitors. Several inhibitors based on known compounds and designed to interact with 150-cavity residues have been reported. However, the dynamics of any of these inhibitors remains unstudied and their viability remains unknown. This work reports the outcome of long-term, all-atom molecular dynamics simulations of four such inhibitors, along with three standard inhibitors for comparison. Each is studied in complex with four representative neuraminidase structures, which are also simulated in the absence of ligands for comparison, resulting in a total simulation time of 9.6 µs. Our results demonstrate that standard inhibitors characteristically reduce the mobility of these dynamic proteins, while the 150-binders do not, instead giving rise to many unique conformations. We further describe an improved RMSD-based clustering technique that isolates these conformations--the structures of which are provided to facilitate future molecular docking studies--and reveals their interdependence. We find that this approach confers many advantages over previously described techniques, and the implications for rational drug design are discussed.
authors.affiliation: Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada.
authors.forename: Kyle T
authors.initials: KT
authors.lastname: Greenway
authors.forename: Eric B
authors.initials: EB
authors.lastname: LeGresley
authors.forename: B Mario
authors.initials: BM
authors.lastname: Pinto
mesh_terms: D001059:Apoproteins / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D020134:Catalytic Domain; D016000:Cluster Analysis; D004795:Enzyme Stability; D009980:Influenza A virus / Q000201:enzymology*; D008024:Ligands; D056004:Molecular Dynamics Simulation; D009439:Neuraminidase / Q000737:chemistry / Q000378:metabolism*; D017433:Protein Structure, Secondary
chemical_list: D001059:Apoproteins; D008024:Ligands; D009439:Neuraminidase
references.citation: Bioorg Med Chem. 2010 Jun 1;18(11):4074-84
references.pmid: 20452227
references.citation: Eur J Med Chem. 2010 Feb;45(2):536-41
references.pmid: 19914748
references.citation: PLoS Pathog. 2011 Oct;7(10):e1002249
references.pmid: 22028647
references.citation: Phys Rev A Gen Phys. 1985 Mar;31(3):1695-1697
references.pmid: 9895674
references.citation: Nat Struct Mol Biol. 2010 Oct;17(10):1266-8
references.pmid: 20852645
references.citation: J Med Chem. 2010 Oct 28;53(20):7377-91
references.pmid: 20873795
references.citation: J Phys Chem B. 2012 May 31;116(21):6137-49
references.pmid: 22553951
references.citation: J Med Chem. 2008 Jul 10;51(13):3878-94
references.pmid: 18558668
references.citation: Eur J Med Chem. 2012 Aug;54:764-70
references.pmid: 22795831
references.citation: Proteins. 2006 Nov 15;65(3):712-25
references.pmid: 16981200
references.citation: Nat Rev Drug Discov. 2007 Dec;6(12):967-74
references.pmid: 18049471
references.citation: J Chem Inf Model. 2009 Oct;49(10):2323-32
references.pmid: 19780597
references.citation: J Chem Theory Comput. 2008 Mar;4(3):435-47
references.pmid: 26620784
references.citation: Antiviral Res. 2009 Apr;82(1):51-8
references.pmid: 19428595
references.citation: Phys Chem Chem Phys. 2010 Jul 28;12(28):7821-39
references.pmid: 20574571
references.citation: J Comput Chem. 2005 Dec;26(16):1668-88
references.pmid: 16200636
references.citation: J Comput Chem. 2004 Jul 15;25(9):1157-74
references.pmid: 15116359
references.citation: Proteins. 2010 Aug 15;78(11):2523-32
references.pmid: 20602360
references.citation: J Mol Biol. 2006 Feb 24;356(3):651-63
references.pmid: 16384583
references.citation: Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
references.pmid: 20057044
references.citation: Nucleic Acids Res. 2007 Jul;35(Web Server issue):W522-5
references.pmid: 17488841
references.citation: Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965
references.pmid: 22258996
references.citation: BMC Res Notes. 2012 Jul 23;5:367
references.pmid: 22824207
references.citation: J Comput Chem. 2010 Jan 30;31(2):455-61
references.pmid: 19499576
references.citation: Nature. 2006 Sep 7;443(7107):45-9
references.pmid: 16915235
references.citation: J Am Chem Soc. 2007 Jun 27;129(25):7764-5
references.pmid: 17539643
references.citation: J Mol Graph Model. 2009 Oct;28(3):203-19
references.pmid: 19656699
references.citation: J Chem Inf Model. 2008 Oct;48(10):2074-80
references.pmid: 18847186
references.citation: Nat Commun. 2011 Jul 12;2:388
references.pmid: 21750542
references.citation: Nat Commun. 2010 Nov 16;1:113
references.pmid: 21081911
references.citation: Drug Discov Today. 2012 Oct;17(19-20):1111-20
references.pmid: 22704956
references.citation: Nature. 2008 Jun 26;453(7199):1258-61
references.pmid: 18480754